Event-dense runway: management frames the coming quarters as a calendar of its own named, scheduled events
The model's full reasoning — Q4 2022 call → NOThe question asks whether management frames the company's near future as a calendar of its own specific, named, already-scheduled events, and treats working through that event sequence as the central story of where the company is heading. Let me analyze the transcript for specific, named, time-anchored events: 1. "we will participate in Susquehanna's 12th Annual Technology Conference on March 2nd in New York and the 35th Annual ROTH Conference on March 13th in Dana Point. Also, we will host an Investor Day on June 13th in Seattle." - These are events, but they are conferences/investor day, not really the company's operational trajectory. 2. "we can and will ramp shipments into that strong demand. That said, our shipment volumes will remain constrained at least into second-half 2023 to wafer-delivery timing and teething issues as we ramp our expanded 300 millimeter post-processing to volume production." - This is a ramp of 300mm post-processing to volume production. This is a specific event with timing (second-half 2023). 3. "we expect first-quarter strength in our Indy reader ICs to more-than-offset the E-family decline. Looking further into 2023, we expect our E-family to significantly outpace and rapidly replace our Indy family." - This is more of a product mix trend. 4. "in November we announced the Impinj M780 and M781, our latest 300 millimeter endpoint ICs." - This was announced in November, already done. 5. "The visionary European retailer continued deploying, contributing strong fourth-quarter gateway revenue. We expect this project to deliver a strong first-quarter revenue and step down as this deployment phase approaches completion." - This is a deployment phase that will step down. It's a specific project. 6. "The Asia based global retailer's self-checkout deployment also generated meaningful fourth-quarter revenue." - This is past. 7. "we expect first-quarter 2023 gross margins between 52% and 53%, with the sequential reduction due to a lighter mix of E-family reader ICs and unanticipated costs in both 300 millimeter endpoint IC post-processing and reader components. We are actively addressing these elevated costs and anticipate gross margins to return to our targeted 53% to 54% range in second-quarter 2023." - This is about gross margins, cost management. 8.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| RCEL | AVITA Medical, Inc. | Q1 2024 | 2024-05-14 | F |
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| BEAT | BioTelemetry's | Q4 2022 | 2023-03-17 | D |
| ARWR | Arrowhead Pharmaceuticals, Inc. | Q4 2022 | 2022-11-28 | D |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| ASTS | AST SpaceMobile, Inc. | Q2 2022 | 2022-08-15 | D |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| ALKS | Alkermes plc | Q3 2018 | 2018-10-23 | C |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| ITCI | Intra-Cellular Therapies, Inc. | Q4 2017 | 2018-03-01 | D |
| PCRX | Pacira BioSciences, Inc. | Q4 2017 | 2018-02-28 | C |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FATE | Fate Therapeutics, Inc. | Q3 2016 | 2016-11-07 | C |
| DUK | Duke Energy Corporation | Q2 2016 | 2016-08-04 | B |
PCRX · Q4 2017 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES Management frames the near-term outlook (2018) as a concrete calendar of its own named, time-anchored events—nerve-block label expansion, C-section study readout, additional Phase 4 study launches, CMS reimbursement decisions, and new partnerships—treating the execution of this sequence as the primary driver of 2018 growth and strategic progress. These are presented as scheduled company actions rather than general market trends, with explicit timing (e.g., mid-year FDA meetings, second-half manufacturing ramp, AAOS programs) and positioned as the central story of where the company is heading.
AU · Q2 2018 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES Management structures the forward outlook around a clear sequence of its own named, time-anchored events—Kibali underground ramp-up and Azambi hydropower station (Q3), Siguiri CIL circuit and power plants (Q4), Obuasi redevelopment milestones (first gold end-2019), Mponeng 6-month backfill plant start (H2), South Africa Section 189 process and wage negotiations (Q3), plus production upticks at multiple sites—presenting these as the primary drivers of the next stage rather than generic market or cost themes.
HROW · Q4 2021 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES The transcript shows management organizing the near-term outlook around a clear sequence of its own named, time-anchored events: AMP-100 PDUFA on October 16 (with launch a few months later), Surface Opthalmics data readout in a few months, Melt Pharmaceuticals top-line data soon after, and internal product 18-month launches, plus MAQ-100 FDA meeting mid-year and relaunch preparations for IOPIDINE/MAXITROL/MOXEZA.